Intra-Arterial Thrombolysis for Acute Stroke in Patients 80 and Older: A Comparison of Results in Patients Younger than 80 Years

References

1. ↵
   Brown RD, Whisnant JP, Sicks JD, et al. Stroke incidence, prevalence and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 1996;27:373–80

   PubMedWeb of Science
2. Wolf PA, D’Agostino RB, Belanger AJ, et al. Probability of stroke: a stroke profile from the Framingham study. Stroke 1991;22:312–18

   Abstract/FREE Full Text
3. ↵
   Manolio TA, Kronmal RA, Burke GL, et al. Short-term predictors of incident stroke in older adults: the cardiovascular health study. Stroke 1996 :1479–86
4. ↵
   Day J. Population projections of the United States by age, sex, race and Hispanic origin: 1995 to 2050. Current Population Reports, series P25–1130. Washington DC: US Bureau of the Census;1996 .
5. ↵
   Smith D. The elderly population. In: Population Profile of the United States: 1997. Current Population Reports, series P23–194. Washington DC: US Bureau of the Census;1998 :50–52
6. ↵
   del Zoppo GJ, Higashida RT, Furlan AJ, et al. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 1998;29:4–11

   Abstract/FREE Full Text
7. ↵
   Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999;282:2003–11

   CrossRefPubMedWeb of Science
8. ↵
   Tanne D, Gorman M, Bates V, et al. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older: The TPA stroke survey experience. Stroke 2000;31:370–75

   Abstract/FREE Full Text
9. Gorman M, Tanne D, Lewandowski C. Centenarian stroke treated with tissue-type plasminogen activator. Cerebrovasc Dis 2002;13:285–87

   CrossRefPubMed
10. Simon J, Sandler D, Pexman J, et al. Is intravenous recombinant tissue plasminogen activator (rt-PA) safe for use in patients over 80 years with acute ischaemic stroke?—The Calgary experience. Age Ageing 2004;33:143–49

    Abstract/FREE Full Text
11. ↵
    Vatankhah B, Dittmar M, Fehm N, et al. Thrombolysis for stroke in the elderly. J Thromb Thrombolysis 2005;20:5–10

    CrossRefPubMedWeb of Science
12. ↵
    Kidwell CS, Saver JL, Carneado J, et al. Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis. Stroke 2002;33:717–24

    Abstract/FREE Full Text
13. ↵
    Anonymous. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med 1985;312:932–36

    PubMed
14. ↵
    Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992;42:976–82

    Abstract/FREE Full Text
15. ↵
    Anonymous. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581–87

    CrossRefPubMedWeb of Science
16. ↵
    Arnold M, Schroth G, Nedeltchev K, et al. Intra-arterial thrombolysis in 100 patients with acute stroke due to middle cerebral artery occlusion. Stroke 2002;33:1828–33

    Abstract/FREE Full Text
17. ↵
    Meade T, North W, Chakrabarti R, et al. Population-based distributions of haemostatic variables. Br Med Bull 1977;33:283–88

    FREE Full Text
18. ↵
    Bauer K, Weiss L, Sparrow D, et al. Aging-associated changes in indices of thrombin generation and protein C activation in humans: normative aging study. J Clin Invest 1987;80:1527–34

    CrossRefPubMedWeb of Science
19. Sakkinen P, Cushman M, Psaty B, et al. Correlates of antithrombin, protein C, protein S, and TFPI in a healthy elderly cohort. Thromb Haemost 1998;80:134–39

    PubMedWeb of Science
20. ↵
    Gleerup G, Winther K. The effect of ageing on platelet function and fibrinolytic activity. Angiology 1995;46:715–18

    PubMed
21. ↵
    Greenberg S, Vonsattel J. Diagnosis of cerebral amyloid angiopathy: sensitivity and specificity of cortical biopsy. Stroke 1997;28:1418–22

    Abstract/FREE Full Text
22. ↵
    de Boer A, Kluft C, Kroon J, et al. Liver blood flow as a major determinant of the clearance of recombinant human tissue-type plasminogen activator. Thromb Haemost 1992;67:83–87

    PubMedWeb of Science
23. ↵
    Tanne D, Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the multicenter rT-PA stroke survey. Circulation 2002;105:1679–85
24. Larrue V, von Kummer RR, Muller A, et al. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001;32:438–41

    Abstract/FREE Full Text
25. ↵
    Gurwitz J, Gore J, Goldberg R, et al. Risk for intracranial hemorrhage after issue plasminogen activator treatment for acute myocardial infarction. Participants in the national registry of myocardial infarction 2. Ann Intern Med 1998;129:597–604

    CrossRefPubMedWeb of Science
26. ↵
    Kase C, Furlan A, Wechsler L, et al. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: The PROACT II trial. Neurology 2001;57:1603–10

    Abstract/FREE Full Text
27. ↵
    Asplund K, Carlberg B, Sundström G. Stroke in the elderly: observations in a population-based sample of hospitalized patients. Cerebrovasc Dis 1992;12:152–57

    CrossRef
28. Al Rajeh S. Stroke in the elderly aged 75 years and above. Cerebrovasc Dis 1994;4:402–06

    CrossRefWeb of Science
29. ↵
    Sharma JC, Fletcher S, Vassallo M. Strokes in the elderly–higher acute and 3 month mortality—an explanation. Cerebrovasc Dis 1999;9:2–9

    PubMedWeb of Science
30. ↵
    Samsa G, Matchar D, Goldstein L, et al. Utilities for major stroke: Results from a survey of preferences among persons at increased risk for stroke. Am Heart J 1998;136:703–13

    CrossRefPubMedWeb of Science